[HIGHLIGHTS] United States authorized the bronchiolitis virus vaccine that was tested in Argentina

The respiratory syncytial virus (RSV) is overloading the Argentine health system. On Wednesday, an RSV vaccine for adults was authorized in the United States and tested in Argentina.

The vaccine, developed by the US laboratory Pfizer, is for people over 60 years of age. It is the secondRSV vaccine that the FDA approves in less than a month: it previously authorized GSK's vaccine for the same population, in a milestone because it is the first time in more than half a century of research that immunization for this virus has been achieved.